Impact of Antiretroviral Therapy on Cardiovascular Disease in HIV Patients
Author Information
Author(s): Jeroen P. H. van Wijk, Manuel Castro Cabezas
Primary Institution: University Medical Center, Utrecht, The Netherlands; Center for Diabetes and Vascular Medicine, St. Franciscus Gasthuis Rotterdam, The Netherlands
Hypothesis
How does combination antiretroviral therapy (CART) affect cardiovascular disease risk in HIV-infected patients?
Conclusion
CART is associated with increased cardiovascular disease risk due to metabolic changes, but the absolute risk remains relatively small.
Supporting Evidence
- The use of CART has led to a significant reduction in AIDS-related mortality.
- However, it has been linked to increased cardiovascular disease risk due to metabolic changes.
- Patients with HIV and lipodystrophy show impaired lipid metabolism and insulin resistance.
- Early diagnosis and treatment of cardiovascular risk factors are recommended for HIV-infected patients.
Takeaway
HIV patients on certain treatments may have heart problems because of changes in their body caused by the medicine, but they still live longer because of the treatment.
Methodology
This review discusses the effects of CART on metabolic risk factors and cardiovascular disease in HIV-infected patients.
Potential Biases
Potential biases may arise from the observational nature of many studies included in the review.
Limitations
The review is based on existing studies, which may have varying methodologies and populations.
Participant Demographics
HIV-infected patients undergoing combination antiretroviral therapy.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website